Last week, we were proud to present two abstracts at the San Antonio Breast Cancer Symposium 2024.
The first abstract presented data from Charing Cross Hospital on Digistain and metastasis-free survival.
The second abstract focused on assessing Digistain’s robustness by assessing its performance against variations in tissue fixation time, reporting its performance across a range of fixation times.
We continue to work to provide recurrence-risk information to clinicians and patients.
https://sabcs.org/Call-for-Abstracts-2024


